Cargando…

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

BACKGROUND: c-Met is a tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF), and both c-Met and its ligand are expressed in a variety of tissues. C-Met/HGF/SF signaling is essential for normal embryogenesis, organogenesis, and tissue regeneration. Abnormal c-Met/HGF/SF signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crosswell, Hal E, Dasgupta, Anindya, Alvarado, Carlos S, Watt, Tanya, Christensen, James G, De, Pradip, Durden, Donald L, Findley, Harry W
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790467/ https://www.ncbi.nlm.nih.gov/pubmed/19939254 http://dx.doi.org/10.1186/1471-2407-9-411

Ejemplares similares

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models
por: Hassan, Wafaa, et al.
Publicado: (2016)

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
por: Peirce, Susan K., et al.
Publicado: (2010)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

Hepatocyte Growth Factor/c-Met Signaling Is Required for β-Cell Regeneration
por: Alvarez-Perez, Juan Carlos, et al.
Publicado: (2014)

Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases
por: Whang, Young Mi, et al.
Publicado: (2019)

Functional and therapeutic relevance of hepatocyte growth factor/c‐MET signaling in synovial sarcoma
por: Imura, Yoshinori, et al.
Publicado: (2016)

Editorial of Special Issue “New Aspects of the Hepatocyte Growth Factor/c-Met System”
por: Ricci, Giulia
Publicado: (2015)

Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
por: Rothenberger, Natalie J., et al.
Publicado: (2017)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Efficacy of c-Met inhibitor for advanced prostate cancer
por: Tu, William H, et al.
Publicado: (2010)

Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?
por: Wang, Xiangdong, et al.
Publicado: (2010)

Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression
por: NOGUCHI, EIICHIRO, et al.
Publicado: (2015)

Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications
por: García-Vilas, Javier A, et al.
Publicado: (2018)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Jet/MET + b/c tagging
por: Komaragiri, Jyothsna Rani
Publicado: (2022)

Isothiocyanatostilbenes as novel c-Met inhibitors
por: Gray, Alana L., et al.
Publicado: (2015)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

c-Met and miRs in Cancer
por: Giglio, Simona, et al.
Publicado: (2015)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors
por: Carracedo, Alma, et al.
Publicado: (2009)

MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET
por: SHENG, XIU-JIE, et al.
Publicado: (2014)

Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target
por: Trovato, Maria, et al.
Publicado: (2017)

The hepatocyte growth factor/c-met pathway is a key determinant of the fibrotic kidney local microenvironment
por: Fu, Haiyan, et al.
Publicado: (2021)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte
por: Cicchini, Carla, et al.
Publicado: (2015)

Hepatocyte growth factor/MET in cancer progression and biomarker discovery
por: Matsumoto, Kunio, et al.
Publicado: (2017)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Expression and functional interaction of hepatocyte growth factor- scatter factor and its receptor c-met in mammalian brain
Publicado: (1994)

c-Met is essential for wound healing in the skin
por: Chmielowiec, Jolanta, et al.
Publicado: (2007)

c-Met as a Target for Personalized Therapy
por: Garajová, Ingrid, et al.
Publicado: (2015)

HGF/c-MET Signaling in Melanocytes and Melanoma
por: Czyz, Malgorzata
Publicado: (2018)

Structural basis of the activation of c-MET receptor
por: Uchikawa, Emiko, et al.
Publicado: (2021)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
por: Wang, Ying, et al.
Publicado: (2016)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
por: Lohberger, Birgit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_22l6avg4ubcfu09nfvujqup26s